Duplex realtime PCR method for Epstein–Barr virus and human DNA quantification: its application for post-transplant lymphoproliferative disorders detection  by Fellner, María Dolores et al.
OD
h
p
M
V
a
C
b
V
a
A
R
A
A
K
E
r
v
P
1
hb r a z j i n f e c t d i s . 2 0 1 4;1  8(3):271–280
The Brazilian Journal of
INFECTIOUS  DISEASES
www.elsev ier .com/ locate /b j id
riginal article
uplex  realtime  PCR  method  for  Epstein–Barr  virus  and
uman DNA  quantiﬁcation:  its  application  for
ost-transplant lymphoproliferative  disorders  detection
aría Dolores Fellnera,∗, Karina Duranda, Marcelo Rodriguezb, Lucía Irazub,
irginia Alonioa, María Alejandra Picconia
Oncogenic Viruses Service, Virology Department, National Institute of Infectious Diseases “Carlos G. Malbrán”, Av. Vélez Sársﬁeld 563,
1282AFF Buenos Aires, Argentina
Operational Team Quality Management, Parasitology Department, National Institute of Infectious Diseases “Carlos G. Malbrán”, Av.
élez Sársﬁeld 563, C1282AFF Buenos Aires, Argentina
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 10 June 2013
ccepted  16 July 2013
vailable  online 2 January 2014
eywords:
BV
eal-time PCR
iral  load
TLD
a  b  s  t  r  a  c  t
Introduction: The quantiﬁcation of circulating Epstein–Barr virus (EBV) DNA is used to moni-
tor  transplant patients as an early marker of Post-Transplant Lymphoproliferative Disorders
(PTLD).  So far no standardized methodology exists for such determination.
Objective:  Our purpose was to develop and validate a real-time PCR assay to quantify EBV
DNA  in clinical samples from transplant recipients.
Methods: A duplex real-time PCR method was developed to amplify DNA from EBV and
from  a human gene. The EBV load was determined in peripheral blood mononuclear
cells  (PBMC), plasma and oropharyngeal tissue from 64 non-transplanted patients with
lymphoid-hypertrophy (Non-Tx), 47 transplant recipients without PTLD (Tx), 54 recipients
with  PTLD (Tx-PTLD), and 66 blood donors (BD). WinPEPI, version 11.14 software was used
for  statistical analysis.
Results:  Analytical validation: the intra and inter-assays variation coefﬁcients were less than
4.5%  (EBV-reaction) and 3% (glyceraldehyde 3-phosphate dehydrogenase – GAPDH reaction).
Linear  ranges comprised 107–10 EBV genome equivalents (gEq) (EBV-reaction) and 500,000–32
human  gEq (GAPDH-reaction). The detection limit was 2.9 EBV gEq (EBV-reaction). Both reac-
tions showed speciﬁcity. Application to clinical samples: higher levels of EBV were  found in
oropharyngeal  tissue from transplanted groups with and without PTLD, compared to Non-
Tx (p < 0.05). The EBV load in PBMC from the groups of BD, Non-Tx, Tx and Tx-PTLD exhibited
increasing  levels (p < 0.05). In BD, PBMC and plasma, EBV loads were undetectable.Conclusions: The performance of the assay was suitable for the required clinical application.The  assay may be useful 
laboratories  from low-inc
© 2013 E
∗ Corresponding author.
E-mail  addresses: oncovir1@anlis.gov.ar, fellnermd@gmail.com (M.D
413-8670  © 2013 Elsevier Editora Ltda. 
ttp://dx.doi.org/10.1016/j.bjid.2013.07.011
Este é um artigo Open Access sob a licençato monitor EBV infection in transplant patients, in particular in
ome regions that cannot afford to use commercial assays.
lsevier Editora Ltda.  
. Fellner).
 
 de CC BY-NC-ND
Este é um artigo Open Access sob a licença de CC BY-NC-ND
i s . 2 0
(272  b r a z j i n f e c t d 
Introduction
The quantiﬁcation of Epstein–Barr virus (EBV) peripheral DNA
is  used to monitor transplant patients as an early marker
of  Post-Transplant Lymphoproliferative Disorders (PTLD).1–3
It has been proven that EBV load in peripheral blood sam-
ples  from transplant patients with PTLD is higher than in
transplant  recipients without this disorder.4–6 Along the last
decade,  different quantitative PCR assays (semi-quantitative,
competitive, real-time) have been used for surveillance, diag-
nosis,  monitoring response to treatment, and determination
of  the degree of immunosupression to be applied. So far, there
is  no reference strategy to determine EBV load, including for
instance  the calibrator, the EBV region to be ampliﬁed, or the
best  sample type for identifying PTLD risk.7,8
No international standards were  available until 2012, when
the  World Health Organization introduced the ﬁrst WHO
International Standard for Epstein–Barr virus, intended to be
used for nucleic acid ampliﬁcation techniques.9 Thus, the lit-
erature  describes a variety of controls used to analytically
validate EBV quantiﬁcation assays, including cell lines,10–12
plasmids with EBV-genome fragments inserted,13,14 and com-
mercially  available controls containing viral particles.15,16 As
no  international standard or consensus-accepted control have
been developed,17–19 each laboratory decided what calibra-
tor  to use to validate its own EBV quantiﬁcation method.
Different fragments of EBV genes were  chosen for ampliﬁca-
tion  in a variety of quantiﬁcation assays, including repeated
(BamHI-W region) or single (EBERs, EBNA-1, LMP-2, etc) viral
genome  regions20,21 with different degrees of sensitivity or
accuracy,  as previously described.22,23 Moreover, several blood
sample  types (peripheral blood mononuclear cells, plasma,
and  whole blood) were analyzed to identify PTLD. Most
studies  described and/or recommended using cell-associated
blood samples over plasma/serum, but both specimen types
appear  to be informative and each laboratory determines its
preference.24,25 Also, the extraction methods, the amount of
sample  to be analysed, the report format and the charac-
teristics of the study populations vary between published
data.7,20,21 Thus, all these factors have affected the compar-
ison between methods.
Several  years ago, our laboratory developed a semiquan-
titative PCR strategy to measure EBV load26 and since
then it has been used to monitor this viral infection in
transplanted population from most of the institutions that
perform  organ transplantation in Argentina. The method
is  quite cumbersome and time-consuming; results demand
at  least 48 hours. Currently, real-time PCR quantiﬁcation
methods are widely applied to assess EBV load due to
their  advantages over conventional PCR assays.3,7,21 More-
over,  the simultaneous ampliﬁcation of an internal control
along  with the target DNA is widely used to detect the pres-
ence  of inhibitors; it also allows to quantify the amount
of  sample present in the reaction, which permits viral load
normalization.10,27
Despite the current availability of commercial assays, many
laboratories  from low income regions are unable to afford
them;  thus, less-costly in-house methods may  be the only
option  to monitor EBV load in transplant patients. Their 1 4;1  8(3):271–280
development and validation could be extremely useful for the
prevention  of PTLD in these settings.
Therefore, the aim of the present study was  to develop and
analytically validate a duplex real-time PCR assay to quantify
EBV  and human DNA in different types of clinical samples,
in  order to determine the EBV load in transplant patients
regarding the risk of PTLD.
Materials  and  methods
Patients  and  samples
Children treated in “Prof. Dr Juan P. Garrahan” Pediatric
Hospital, Austral University Hospital, “Sor María Ludovica”
Children’s Hospital” and Favaloro Foundation, and blood
donors  of the “J. F. Mun˜iz”  Infectious Diseases Hospital were
included  as follows:
A)  64 non-transplanted patients with lymphoid hypertrophy
in  the oropharyngeal tissue.
(B) 101 solid organ transplant patients (75 liver, 24 kidney,
2  heart), 54 of them with histological diagnosis of PTLD
(including categories 1, 2, 3 and 4), according to the World
Health  Organization: IARC, 2008.28
(C) 66 blood donors, with negative results for all infections
screened in routine blood bank protocol (hepatitis C
virus,  hepatitis B virus, human T lymphotropic virus I/II,
human  immunodeﬁciency virus, syphilis, brucellosis, and
Chagas′ infection).
All  patients were infected with EBV according to the pres-
ence  of IgG antibodies against viral capsid antigen (VCA)
and/or  viral DNA in peripheral blood.
Patients in the transplant group were  on an immuno-
suppressive regimen consisting of cyclosporine, tacrolimus
or  sirolimus, azathioprine or mycophenolate mofetil and
steroids.
Peripheral  blood and oropharyngeal lymphoid tissue sam-
ples  were taken due to oropharyngeal lymphoid hypertrophy,
following the treatment protocol for transplant and non-
transplanted patients. An informed consent was obtained in
all cases as per the Helsinki declaration and other national
and  international regulations.
Peripheral blood mononuclear cells (PBMC) and plasma
were  separated from 2.5 to 5 mL  of EDTA-anticoagulated
whole blood samples by centrifugation on a density gradi-
ent  (Histopaque-1077, Sigma–Aldrich) and stored at −20 ◦C.
Oropharyngeal lymphoid tissue samples obtained through
surgical  removal from patients with lymphoid hypertrophy
were  stored at −80 ◦C.
Controls  and Calibrators
-  EBV-speciﬁc reaction (EBNA-1 reaction)A plasmid containing a deleted fragment of the EBNA-1
coding gene from the EBV genome was used as calibrator of
the  real-time PCR quantiﬁcation method. It had been previ-
ously  developed in our laboratory to be used as competitor in
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 quantitative competitive PCR. It was  quantiﬁed by spectro-
hotometry at 260 nm and stored at −80◦ C.
Calibrators were  generated to exhibit the same character-
stics  as the clinical samples. Thus, for the EBNA-1 reaction,
wo  types of calibrators were prepared:
 Calibrators representative of cell-associated samples
(peripheral blood mononuclear cells, tissues): serial dilu-
tions  of the PEBNA-1 were  performed and placed on a
background of 366 ng of commercially available human
DNA  (equivalent to 105 human cells).26
 Calibrators representative of cell-free samples
(plasma/serum): serial dilutions of the PEBNA-1 were
performed without the human DNA background.
This allowed studying seven levels of EBV genome equiv-
lents:  107, 106, 105, 104, 103, 102 and 10 for each type of
alibrator.
 Human-speciﬁc reaction (GAPDH-reaction)
Commercially available human DNA was  used as a positive
ontrol  for the glyceraldehyde 3-phosphate dehydrogenase
GAPDH) reaction (Human Genomic DNA, Roche); which was
uantiﬁed  by spectrophotometry at 260 nm,  aliquoted and
tored  at −80◦ C.
Thus, seven calibrators were generated by 1/5 dilution
f  the commercially available human control, representing:
 × 105, 105, 2 × 104, 4 × 103, 8 × 102, 160 and 32 human cells.
ll these DNA concentrations were analyzed in the presence
f  high (106 EBV genome equivalents) or low (10 EBV genome
quivalents) amounts, or in absence of the control PEBNA-1.
EBNA-1 sequencing
EBNA-1 was  characterized by sequencing with the BigDye
erminator Sequencing kit v3.1, according to manufac-
urer’s recommendations in the Genetic Analyzer 3500 (Applied
iosystems-Hitachi). The sequence analysis was  performed
sing  the Sequencing Analysis Software v5.2 (Applied Biosys-
ems).  The PEBNA-1 sequence was  compared with that of the
rototypic EBV strain, B95-8, applying the BioEdit Sequence
lignment editor v7.0.9.
NA  extraction
NA from PBMC and oropharyngeal tissue samples was
xtracted  as previously described.26
Plasma DNA was  extracted using the QIAmp DNA mini kit
QIAgen)  according to manufacturer’s instructions, taking into
ccount  the suggested recommendations for free viral DNA
xtraction.
eal-time  PCR  method  for  EBV  DNA  quantiﬁcation duplex real-time PCR strategy that simultaneously ampli-
es  portions of the EBV and of the human genome was
pplied, encoding the EBNA-1 protein and the glyceraldehyde
-phosphate dehydrogenase (GAPDH) enzyme respectively.4;1 8(3):271–280  273
For  the primers/probe design, the Primer Express soft-
ware  2.0 (Applied Biosystems) was  applied on the sequence
of  the PEBNA-1 to obtain MGB (Minor Groove Binding) type
primers/probe, for the EBNA-1-reaction and on a conserved
portion of the reference sequence of human GAPDH (AC
000144,  GenBank) to obtain TAMRA (tetramethylrhodamine) type
primers/probe for the GAPDH-reaction. In both cases, a pair
of  primers and probe for each reaction was  selected, tak-
ing  into account the most favourable condition with respect
to  their score and secondary structure; also, the possibility
of  non-speciﬁc cross-reactions was ruled out by analyzing
their  sequences with the Basic Local Alignment Search Tool
(BLAST).  The selected primers/probes were  as follows: EBNA-
1  reaction: 5′ CCGCTCCTACCTGCAATATCA  3′ (forward primer)
and  5′ GGAAACCAGGGAGGCAAATC 3′ (reverse primer); 5’ VIC-
TGCAGCTTTGACGATGG-MGB 3’ (probe). They ampliﬁed a 73
base  pair fragment.
GAPDH  reaction: 5′ GGTGGTCTCCTCTGACTTCAACA 3′ (for-
ward  primer); 5′ GTGGTCGTTGAGGGCAATG 3′ (reverse primer)
and  5′ FAM-CCACTCCT CCACCTTTGACGCTGG-3′ TAMRA
(probe).  They ampliﬁed a 79 base pair fragment.
Ampliﬁcation was  performed in a ﬁnal reaction volume of
25  l, containing 1X TaqMan Universal Master Mix  with AmpErase
UNG  (Applied Biosystems), 0.3 M of EBV-primers, 0.05 uM
of  GAPDH-primers, 0.1 M of EBV-probe and GAPDH-probe
and the DNA to be ampliﬁed (calibrators for EBV or GAPDH
reactions as described, 366 ng (equal to 105 cells) of DNA  from
PBMC  or oropharyngeal tissue or a volume of DNA extracted
from  plasma (representing 30 l of plasma). The ampliﬁcation
was  carried out using the 7500 real-time PCR System (Applied
Biosystems) and the cycle conditions were  as follows: 50 ◦C
2  min; 95 ◦C 10 min, followed by 45 cycles of 95 ◦C 15 s, 60 ◦C
1  min.
The  EBV load in PBMC DNA was  expressed as the number
of  EBV genome equivalents per 105 PBMC. The normalized EBV
load  was  estimated from the results of the EBNA-1 and GAPDH
reactions  (105 × EBNA-1 load/GAPDH load) and the unnor-
malized load from the result of the EBNA-1 reaction when
measuring 366 ng of PBMC DNA estimated by spectrophoto-
metry. The plasma EBV load was expressed as the number
of  EBV genome equivalents per mL  of plasma multiplying
the EBNA-1 reaction result by a factor of 33.3 (consider-
ing that the amount of plasma analyzed was 30 L, thus
30  L × 33.3 = 1000 L).
Analytic  validation
Master batches of all controls and reagents were  prepared for
the  analytical validation.
The  precision and dynamic range of the EBNA-1 and
GAPDH reactions were  determined in a one-day-run, with
four  replicates of each set of seven calibrators described
over 20 consecutive days. The intra-assay (repeatability) and
inter-assay  (precision) variations were calculated using the
CLSI/NCCLS.  2005. EP15-A2 procedure.29 The linear range
was  analysed using polynomial regression according to the
30CLSI/NCCLS.  2003. EP6-A procedure.
The EBNA-1 reaction detection limit was determined using
series  of four samples prepared by diluting a high concentra-
tion  EBV control (PEBNA-1) to dilutions containing 1, 2, 4 and 8
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Table 1 – Description of the patients.
Patients N Sex M/F Agea Organ
transplanted
Agea at
transplant
Cause of
transplant
Transplant
patients
Non-PTLD 47 0.9 9.7
(0.5–19)
Liver (42)
Kidney (5)
2.8
(0.5–12)
Liver: FHF, BA
EC,  GL
Kidney: CRF
PTLD 54 1.5 8.0
(1–18)
Liver (35)
Kidney (19)
Heart  (2)
4.7
(0.5–10)
Liver: FHF, BA,
EC,  GL
Kidney: CRF
Heart:  UC
Non-transplanted
patients
64 1.8 7.0
(0.5–19)
– – –
Blood donors 66 2.3 36
(18–61)
– –
biliary atresia; EC: sclerosing cholangitis; GL: glycogenosis type 1B and 3.
B
B
95-8
10
60
110
160
210
260 280270
220 230 240 250
170 180 190
EBV-MGB  Probe
200
120 130 140 150
70 80 90 100
35 bp deletion
CATTGAGTCG TCTCCCCTTT GGAATGGCCC
GGCCCACTAA GGGAGTCCAT TGTCTGTTAT TTCATTGTCT TTTTACAAAC
TCATATATTT
CAAAGCCCGC
GATGGAGTAG ATTTGCCTCC
Reverse EBV-primer
CGCGGAGGGT GATGACGGAG ATGACGGAGA TGAAGGAG
CTGGTTTCCA CCTATGGTGG AAGGGGCTGC
Forward EBV-Primer
TCCTACCTGC AATATCAAGG TGACTGTGTG CAGCTTTGAC
GCTGAGGGTT TGAAGGATGC GATTAAGGAC CTTGTTTTGC
CTGGACCCGG CCCACAACCT
20 30 40 50
95-8
B 95-8
B 95-8
B 95-8
B 95-8
PEBNA-1
PEBNA-1
PEBNA-1
PEBNA-1
PEBNA-1
PEBNA-1
Fig. 1 – Characterization of the EBV-fragment sequence
inserted in the PEBNA-1. The 35 bp deletion in the EBV
fragment of PEBNA-1 and the forward/reverse primers. (– – –)
and probe (—) used in the EBV-speciﬁc real-time PCRa Age in years, mean and range. FHF: fulminant hepatic failure; BA: 
CRF: Chronic renal failure. UC: unknown cause
copies of EBV genome equivalents, either in a background of
human  DNA representing 105 cells (366 ng) or without the DNA
background.  Twenty replicates of each sample were tested in
three different runs. The detection limit was  calculated using
the  probit regression function.
The ampliﬁcation efﬁciency of each run was  calculated
using the following formula: E = (10−1/m − 1) × 100.31
To analyze EBNA-1 reaction speciﬁcity, DNA from the
Epstein–Barr virus (PEBNA-1 and RAJI cell line), from the human
members of the Herpesviridae family (herpes simplex virus,
cytomegalovirus, varicella-zoster virus, human herpesvirus
6  and human herpesvirus 8), from different origin human
cells  (ﬁbroblast, human embryonic kidney (HEK-293) cell
lines)  and commercial source human DNA (Human Genomic
DNA,  Roche) were  analysed. To analyze GAPDH reaction
speciﬁcity, DNA from human cell lines (HEK-293 and human
ﬁbroblast), commercial source human DNA and plasmids
containing different herpesvirus sequences (herpes simplex,
varicella-zoster, cytomegalovirus, and human herpesvirus 6)
were studied.
Statistical  analysis
The precision box-plot, dose response curve and regres-
sion  analysis were  performed with Microsoft Excel 2003.
WinPEPI version 11.14 software was  used for statistical anal-
yses.  Medians and conﬁdence intervals were obtained with
Describes,  version 2.33. Differences between medians of con-
tinuous  variables were  analyzed using the Mann–Whitney or
Kruskal–Wallis test for two groups (program Compare 2, version
2.57)  or more  than two groups (Etcetera, version 2.56). p-Values
below  0.05 were  considered signiﬁcant.
Results
Description  of  the  study  population
The population characteristics are described in Table 1.Characterization  of  PEBNA.-1 control
Fig. 1 shows the result of the analysis of the EBV frag-
ment sequence inserted in PEBNA-1 compared with that of thereaction are indicated.
B95-8 prototype strain, according to which both fragments
were  identical except for the 35 bp deletion.
Analytic  validation  of  the  real-time  PCR  EBV
quantiﬁcation  assay
- Precision
Fig. 2 shows the precision of the EBNA-1 reaction for cell-
associated samples at the different EBV levels studied during
the  analytical validation.
No  differences were observed in the cycles’ threshold
results obtained by the EBNA-1 reaction between the calibra-
tors  representing cell-associated samples or cell-free samples
(data  not shown). For the GAPDH reaction, the intra- and
inter-run  variation coefﬁcients were less than 3%,  at all con-
centrations  studied (data not shown).
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representative of cell-associated samples. The box plot
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of  cell-associated samples during the analytical validation;
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 Linear range
For  the EBNA-1 reaction, the cycles thresholds’ regression
nalysis, obtained from the EBV calibrators, was applied to
etermine  the linear range (Fig. 3). The standard error of the
egression  (taken as a measure of the model adjustment) was
ot  higher than those for the second and third order models;
t  was  concluded that the best match for this data set was
he  linear order model. Thereby, the reaction showed linearity
cross  the whole range of concentrations studied (between 107
nd 10 EBV genome equivalents), both for cell-associated and
ell-free  calibrators.
A  similar analysis for the GAPDH reaction showed a linear
ange  between 500,000 and 32 human genome copies (data not
hown).  No differences were noted in the reaction results at
ll  human DNA levels studied either in absence or presence of
ow  or high concentrations of EBV genome equivalents (data
ot  shown).
 Detection limit
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ig. 3 – Dose response curve adjustment to linear and
uadratic models.Fig. 4 – Detection limit of the EBV-speciﬁc reaction.
Fig. 4 shows the minimum concentration of EBV genome
equivalents of the calibrator representing the cell-associated
samples that could be readily detected.
The probit regression analysis showed that the detection
limit  is about three EBV genome equivalents per 105 cells. A
similar  detection limit was obtained for calibrators represent-
ing  cell-free samples.
The  GAPDH-reaction detection limit was not studied since
the  determination of the EBV load requires analysing close to
105 cells DNA (equivalent to 366 ng) from each sample. A very
low  amount of initial DNA may  result from errors in loading
the  sample, DNA quality, or the presence of inhibitors; in all
such  cases the assay must be repeated.
- Efﬁciency
Both in the analytical validation and when studying the
clinical  samples, an ampliﬁcation efﬁciency of 90–110% for
both  reactions was  required in order to consider that an assay
was  acceptable.
-  Speciﬁcity
When analysing the EBNA-1 reaction, a positive signal
was  only seen with the EBV controls’ DNA; no ampliﬁca-
tion was detected when analysing DNA from other human
members of the Herpesviridae family (herpes simplex virus,
cytomegalovirus, varicella-zoster virus, human herpesvirus
6  and human herpesvirus 8) or from human origin. More-
over,  the GAPDH reaction gave a positive signal with different
human  DNAs but no signal with plasmid or various Herpesvirus
(herpes  simplex virus, cytomegalovirus, varicella-zoster virus
and  human herpesvirus 6) DNAs.
Correlation  of  normalized  and  unnormalized  EBV  loads
measured  in  PBMC  DNA
The results of the EBV load measured in PBMC DNA  repre-
senting  105 cells estimated by spectrophotometry (equal to
366  ng) (unnormalized load) and the GAPDH-reaction (nor-
malized  load) showed a linear correlation (data not shown).
In  some cases, when the amount of DNA was measured by
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Table 2 – EBV viral load measure in different virus persistence sites.
Study groups N Median of normalized EBV load (range) CIa
Lymphoid tissue
(EBV  gEq/105 cells)
Peripheral blood
mononuclear cells
(EBV  gEq/105 cells)
Plasma (EBV gEq/mL)
Blood donors 66 – <3
100%: <100
<100
100%:  <100
Non-transplanted
patients with LH
64  4 (<3–822)
95.7%: 3–12
<10 (<3–124.1)
95.6%: <10
<100
100%:  <100
Transplant patients
without  PTLD
47  133.5 (<3–9786)
96.9%: 3–479
11.5 (<3–432.6)
96.6: <3–16
<100  (<100–3107)
97.2%: <100
Transplant patients
with  PTLD
54 239 (3–1,775,353)
95.6%: 52–373
21.5 (<3–32,181)
96.7%: 8–37
<100  (<100–23,997)
95.6%: <100
ntervPTLD, post-transplant lymphoproliferative disorders; CI, conﬁdence i
spectrophotometry (performed prior to the ampliﬁcation reac-
tion), the amount of DNA was  underestimated.
EBV  load  in  different  clinical  states  and  kinds  of  samples
In order to analyse the differences in the EBV load between
transplant and non-transplanted patients in various clin-
ical  situations, we  compared the following groups: blood
donors  (healthy carriers), individuals with lymphoid tissue
hypertrophy, organ-recipients who did not develop PTLD and
transplant  patients with histological diagnosis of PTLD. In the
blood  donors group, only compartments of peripheral blood
mononuclear cells and plasma were studied, since lymphoid
tissue  samples were  not available (Table 2).
-  Lymphoid tissue
In  non-transplanted patients with oropharyngeal
lymphoid hypertrophy, EBV DNA was  detectable in
70.3%  of the lymphoid tissue samples (≥3 EBV genome
equivalents/105 cells) and quantiﬁable in 37.5% (≥10 EBV
genome  equivalents/105 cells). In transplant patients without
PTLD,  EBV DNA was  detectable and quantiﬁable in 85.0%
and  65.0% of samples, respectively; while in PTLD cases, the
values  increased to 100% and 87.1%, respectively. Signiﬁcantly
higher  levels of EBV were  found in oropharyngeal tissue from
transplanted  groups with and without PTLD, compared to
non-transplanted patients (p < 0.05), but there was  no differ-
ence  between transplant recipients with and without PTLD
(p  > 0.05).
- Peripheral blood mononuclear cells
In blood donors, 100% of the PBMC samples’ DNA showed
undetectable EBV DNA levels; in non-transplanted patients
with  oropharyngeal lymphoid tissue hypertrophy, 61.2% of
the  DNA obtained from PBMC samples carried detectable (≥3
EBV  genome equivalents/105 PBMC) and 24.5% quantiﬁable
(≥10 EBV genome equivalents/105 PBMC) EBV load; in trans-
plant  patients without PTLD, 65.8% of the PBMC samples
showed detectable EBV DNA and 42.1% quantiﬁable levels,
and  in organ recipients with PTLD, 97.9% of PBMC samples
showed detectable EBV DNA which in 64.6% was  quantiﬁ-
able.  The EBV load in PBMC from the groups of blood donors,al; EBV gEq, EBV genome equivalents; LH, lymphoid hypertrophy.
non-transplanted individuals, transplanted groups with and
without  PTLD showed signiﬁcantly increasing levels (p < 0.05).
-  Plasma
In three transplant patients, the GAPDH reaction was  neg-
ative,  indicating inhibition or absence of plasma-extracted
DNA; those were excluded from the analysis. In 100% of the
plasma  samples from blood donors and non-transplanted
patients with lymphoid hypertrophy, EBV DNA  was  not
detectable. In transplant patients without PTLD, viral DNA
was  detectable (≥100 EBV genome equivalents/mL) in 11.9%
and  quantiﬁable (≥333 EBV genome equivalents/mL) in 4.8%
of  the samples tested; in transplant recipients with PTLD, EBV
DNA  was detectable in 23.2% and quantiﬁable in 21.4% of the
samples.  In the plasma compartment no signiﬁcant EBV load
difference  was  detected between transplant recipients with
and  without PTLD (p > 0.05).
Discussion
The above described method was  designed to detect viral
loads  higher than those found in the peripheral blood of
healthy  carriers. Thus, we decided to analyze a DNA amount
equivalent to 105 human cells from each transplant patient,
as  already described.26 Since the cell quantiﬁcation meth-
ods  available were not very reproducible, instead of cells, we
preferred  to quantify the cellular DNA by either spectropho-
tometry or co-ampliﬁcation of human GAPDH gene. When
comparing the normalized and unnormalized EBV loads, a
more  accurate estimation of the PBMC DNA quantity resulted
from  the GAPDH reaction than from the spectrophotometrical
measurement. This could probably be explained because the
quantiﬁcation  of human and EBV DNA is made in the same
tube  in the real-time PCR assay, while the spectrophotometry
quantiﬁcation is done prior to the ampliﬁcation reaction and
pipetting  or dilution errors are therefore disregarded. Thus,
the  EBV load normalization may  allow for better comparison
between samples from different individuals or from the same
patient  taken at different times.
The above described EBV quantiﬁcation method proved to
be  linear in a wide range of concentrations for both reac-
tions.  In the case of the EBNA-1 reaction, the EBV DNA
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oncentrations expected in clinical samples may  vary from
oncentrations similar to those seen in healthy carriers (unde-
ectable  with this methodology) to very high levels as those of
ransplant  patients with neoplastic PTLD.3,20 Therefore, this
eaction’s  linear range is appropriate for the required clinical
urposes.  On the other hand, the GAPDH-reaction also showed
 broad dynamic range; however, in this case, the expected
mount of DNA to be analyzed in each clinical sample may
ary  less since the DNA quantity is previously determined by
pectrophotometry. Besides, it should be mentioned that by
sing DNA from PBMC obtained from a ﬁxed blood volume,
ariations between different sample amounts will depend
n  the differences in PBMC concentration. Since solid organ
ransplant  patients usually exhibit normal leukocyte counts
between  5000 and 11,000 cells per l), the expected vari-
tion  between samples may  be small. Thus, the GAPDH
eaction dynamic range is also suitable for the purpose of the
ssay.
The  obtained intra- and inter-assay variation coefﬁcients
atched the criteria established for this method and were
lso  consistent with published data.22,23,27 Moreover, the
ccuracy levels were  adequate for clinical applications, i.e.
onitoring  EBV DNA levels in transplant patients, in which
 small variation may  be informative.32,33 Also, since the
ethod was  developed for patients infected with EBV, with
mphasis  on those carrying high amounts of circulating viral
opies,  the detection limit obtained was  appropriate for clin-
cal  purposes and coincided with that described in other
tudies.22,23,34
In this context, the present study analyzed EBV DNA lev-
ls  in different types of clinical specimens representing viral
ersistence  sites35 and various clinical situations. Thus, the
BV  load obtained in oropharyngeal tissue from the group of
on-transplanted patients was  similar to previously described
ata.36,37 Moreover, among the limited literature describing
BV levels in tonsils, slightly higher load values than those
ound  in this study have been reported.38,39 These differ-
nces could be explained by the way  of expressing the result:
ean38 vs. median (present study), or may  be due to the dif-
erent  ampliﬁed genomic fragments: the repeated BamHI-W
egion39 vs. the single EBNA-1 region (present study). Also,
he  median EBV load obtained from the transplanted group
ithout  PTLD exhibits a wide range, which could be divided
nto  two subgroups of patients: one with viral loads simi-
ar  to those seen in non-transplanted patients and the other
ith  higher loads. It should be mentioned that two subgroups
“low-load carriers” and “high-load carriers” – had been previ-
usly  differentiated by measuring EBV in DNA from peripheral
ononuclear cells of transplant recipients without PTLD.40,41
ccording to our results, those descriptions coincide with
ndings  in the oropharyngeal lymphoid tissue of transplant
atients.
Otherwise, the EBV load measured in PBMC was unde-
ectable in all blood donors, i.e. lower than that described in
 similar control group.27 This difference could be due to the
nitial  DNA quantity that was  ampliﬁed (around 3-fold larger
han  in this study). In addition, in this report both in plasma
nd  PBMC from blood donors and in plasma from children
ith  oropharyngeal lymphoid hypertrophy, EBV loads were
onsistent  with previously described viral levels.15,16,42,434;1 8(3):271–280  277
In transplant patients, the increased EBV load reported
in  the literature in comparison with healthy carriers is vari-
able.  In this study, the ranges of EBV DNA load in PBMC
from  transplant patients without PTLD were  similar to pre-
viously  informed data,12,35,44,45 albeit more  limited than in
other  reports.27 The difference could be explained by the
characteristics of the study groups: adults receiving heart
transplantation,27 while in this work the transplanted group
without  PTLD were  children, mainly liver and kidney trans-
plantation recipients. The degree of immunosuppression used
after heart transplantation is more  pronounced than after
kidney  and liver transplantation.2,46 Furthermore, the higher
the  dose of immunosupressive drugs applied, the more  likely
the  occurrence of viral activation which results in larger EBV
loads.
In  transplant patients with EBV-associated PTLD, high lev-
els  of EBV DNA have often been reported, measured in the
cellular  fraction and plasma of peripheral blood. However, the
number  of EBV copies reported by different authors varies.3,7,8
In this work, the median EBV loads and their range in PBMC
from  transplant patients with PTLD showed the highest lev-
els  of EBV DNA. Nevertheless, the EBV load ranges were very
wide  and included almost 35% of the EBV loads below 10
EBV  genome equivalents, which correspond to patients with
early  PTLD stages (data not shown). Thus, some PTLD cases
have  shown EBV levels in PBMC lower than those described
in  the literature. The disagreements could be explained by
differences  in the methodological strategies applied and also
because  a larger number of cases with early PTLD stages were
analyzed  in this report.
The  EBV load ranges in plasma samples from the trans-
planted group without PTLD were  similar to the already
described data,15,44,47 whereas in transplant patients with
PTLD, the higher EBV levels resembled previously obtained
information,44 but were lower, or the ranges narrower than
those  described by other authors.15,22,47,48 It has been noted
that most of the PTLD patients had undetectable viral DNA
levels  in plasma; this is consistent with reports of trans-
plant  patients with EBV-associated pathology.49 Nevertheless,
the  differences in the levels of EBV plasma loads between
this  study and others can be explained by the different
methodologies and also by the PTLD category analyzed. Most
reports  studied only patients diagnosed with neoplastic-
PTLD.15,22,47,48
An EBV International Standard has recently been made
available9; the present results agree with previous reports
on  the convenience of its use to validate quantiﬁcation EBV
assays,  and emphasize the need for a reference methodologi-
cal  strategy to measure EBV loads (calibrator, method, type of
clinical  sample, and cut-off values).
Finally, while commercial assays may  improve standard-
ization, they are more  expensive than in-house assays. On  the
other  hand, in-house assays may  lack validation and require
additional efforts to standardize. These last attempts may
be  especially suitable for low-resource settings, where an in-
house  assay could mean the only affordable alternative for
some  laboratories to monitor PTLD risk in transplant recipi-
ents.  Thus, an assay with a detailed analytical validation that
follows  the International Organization for Standardization
(ISO) guidelines may  represent a very attractive alternative for
i s . 2 0
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low resource laboratories when assessing its possible imple-
mentation
Conclusions
This real-time PCR quantiﬁcation assay could be used to follow
EBV  infection in transplant patients. Its performance matched
the  required clinical applications. In addition, it was  proven to
detect EBV DNA levels higher than those found in the periph-
eral  blood compartment (PBMC and plasma) of blood donors,
as  those described in the transplanted population. It may  be
useful  to differentiate transplant patients with and without
PTLD  in different clinical samples. Furthermore, it could be
used  for the clinical management of other EBV-associated
diseases. This in-house methodology translate into a less
expensive  and more  accessible alternative than commercial
EBV  load assays, especially valuable for laboratories in low
income  regions.
Also,  taking into account the results obtained in the trans-
planted  population and the data reported, the analysis of EBV
loads  in transplant patients with different PTLD stages could
be  useful in identifying the best way  to detect PTLD risk.
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